112 related articles for article (PubMed ID: 37308118)
1. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Grover S; Zucker SD
J Natl Compr Canc Netw; 2023 Jun; 21(6):617-626.e3. PubMed ID: 37308118
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Zucker SD; Grover S
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1444-1452.e4. PubMed ID: 38401693
[TBL] [Abstract][Full Text] [Related]
3. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM
Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398
[TBL] [Abstract][Full Text] [Related]
5. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
6. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Choi J; Kim GA; Han S; Lim YS
Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-related hepatitis: real-world experience from a tertiary centre.
Cheung V; Gupta T; Payne M; Middleton MR; Collier JD; Simmons A; Klenerman P; Brain O; Cobbold JF
Frontline Gastroenterol; 2019 Oct; 10(4):364-371. PubMed ID: 31656561
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
Torgersen J; Newcomb CW; Carbonari DM; Rentsch CT; Park LS; Mezochow A; Mehta RL; Buchwalder L; Tate JP; Bräu N; Bhattacharya D; Lim JK; Taddei TH; Justice AC; Lo Re V
J Hepatol; 2021 Dec; 75(6):1312-1322. PubMed ID: 34333102
[TBL] [Abstract][Full Text] [Related]
10. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.
Patrinely JR; McGuigan B; Chandra S; Fenton SE; Chowdhary A; Kennedy LB; Mooradian MJ; Palmeri M; Portal D; Horst SN; Scoville EA; Long GV; Shi C; Mehnert JM; Sullivan RJ; Salama AK; Sosman JA; Menzies AM; Johnson DB
Oncoimmunology; 2021 Feb; 10(1):1875639. PubMed ID: 33628621
[TBL] [Abstract][Full Text] [Related]
11. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
[TBL] [Abstract][Full Text] [Related]
12. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
13. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M; Barreira-Díaz A; Callejo-Pérez A; Muñoz-Couselo E; Díaz-Mejía N; Díaz-González Á; Londoño MC; Salcedo MT; Buti M
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):732-740. PubMed ID: 35487453
[TBL] [Abstract][Full Text] [Related]
14. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
Björnsson HK; Gudbjornsson B; Björnsson ES
J Hepatol; 2022 Jan; 76(1):86-92. PubMed ID: 34487751
[TBL] [Abstract][Full Text] [Related]
15. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study.
Kirpich IA; Solovieva NV; Leikhter SN; Shidakova NA; Lebedeva OV; Sidorov PI; Bazhukova TA; Soloviev AG; Barve SS; McClain CJ; Cave M
Alcohol; 2008 Dec; 42(8):675-82. PubMed ID: 19038698
[TBL] [Abstract][Full Text] [Related]
16. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Gauci ML; Baroudjian B; Bédérède U; Zeboulon C; Delyon J; Allayous C; Madelaine I; Eftekhari P; Resche-Rigon M; Poté N; Paradis V; Durand F; Lebbé C; Roux O; Bouattour M;
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101491. PubMed ID: 32773362
[TBL] [Abstract][Full Text] [Related]
17. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a pharmacy consult service for evaluation of immune checkpoint inhibitor related adverse events at a large community hospital.
Kamta J; Magruder B; Hymel L
J Oncol Pharm Pract; 2021 Dec; 27(8):1821-1828. PubMed ID: 33176559
[TBL] [Abstract][Full Text] [Related]
19. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
20. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study.
Ngu JH; Gearry RB; Frampton CM; Stedman CA
Hepatology; 2013 Jun; 57(6):2399-406. PubMed ID: 23359353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
